Similar articles

• Gemcitabine--a major advance?

  Thomas A, Steward WP. Thomas A, et al. Ann Oncol. 1998 Dec;9(12):1265-7. doi: 10.1023/a:1008498219576. Ann Oncol. 1998. PMID: 9932153 No abstract available.
• Gemcitabine doublets in advanced pancreatic cancer: should we move on?

  Rocha Lima CM, Flores AM. Rocha Lima CM, et al. J Clin Oncol. 2006 Jan 20;24(3):327-9. doi: 10.1200/JCO.2005.03.8315. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344312 No abstract available.
• Gemcitabine in the treatment of metastatic pancreatic cancer.

  Hilbig A, Oettle H. Hilbig A, et al. Expert Rev Anticancer Ther. 2008 Apr;8(4):511-23. doi: 10.1586/14737140.8.4.511. Expert Rev Anticancer Ther. 2008. PMID: 18402518 Review.
• [Gemzar (gemcitabine)--a new chemotherapeutic agent for pancreatic cancer].

  Merimsky O, Chaitchik S. Merimsky O, et al. Harefuah. 1997 Sep;133(5-6):208-12. Harefuah. 1997. PMID: 9461693 Review. Hebrew. No abstract available.
• [Concurrent chemoradiation therapy with gemcitabine for advanced or relapsed pancreatic tumors].

  Ioka T, Nakaizumi A, Tanaka S, Yamazaki H, Nishiyama K. Ioka T, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:248-53. Nihon Rinsho. 2006. PMID: 16457260 Review. Japanese. No abstract available.